Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -5.26% Market Closed
Market Cap: 189.3m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

Arovella Therapeutics Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arovella Therapeutics Ltd
Cash Equivalents Peer Comparison

Comparables:
MYX
NEU
BOT
PBP
VLS

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Arovella Therapeutics Ltd
ASX:ALA
Cash Equivalents
AU$12.7m
CAGR 3-Years
24%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cash Equivalents
AU$2.6m
CAGR 3-Years
-48%
CAGR 5-Years
-32%
CAGR 10-Years
-19%
Botanix Pharmaceuticals Ltd
ASX:BOT
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Cash Equivalents
AU$12.8m
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
34%
Vita Life Sciences Ltd
ASX:VLS
Cash Equivalents
AU$27.7m
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
11%

See Also

What is Arovella Therapeutics Ltd's Cash Equivalents?
Cash Equivalents
12.7m AUD

Based on the financial report for Jun 30, 2024, Arovella Therapeutics Ltd's Cash Equivalents amounts to 12.7m AUD.

What is Arovella Therapeutics Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
24%

Over the last year, the Cash Equivalents growth was 146%. The average annual Cash Equivalents growth rates for Arovella Therapeutics Ltd have been 24% over the past three years , 24% over the past five years .

Back to Top